ME2 Medicare Part D Cost Sharing And Specialty Drug Initiation In Newly Diagnosed Chronic Myeloid Leukemia Patients
Doshi J, Li P, Huo H, Pettit A, Kumar R, Huntington S, Weiss B. ME2 Medicare Part D Cost Sharing And Specialty Drug Initiation In Newly Diagnosed Chronic Myeloid Leukemia Patients. Value In Health 2016, 19: a3. DOI: 10.1016/j.jval.2016.03.035.Peer-Reviewed Original ResearchHigh cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
Doshi JA, Li P, Huo H, Pettit AR, Kumar R, Weiss BM, Huntington SF. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia. The American Journal Of Managed Care 2016, 22: s78-86. PMID: 27270157.Peer-Reviewed Original ResearchConceptsChronic myeloid leukemiaTyrosine kinase inhibitorsHigher cost sharingMedicare Part DDrug initiationMyeloid leukemiaLIS patientsInitiation of TKIsRetrospective claims-based analysisOral tyrosine kinase inhibitorNon-LIS patientsMonths of diagnosisClaims-based analysisPart DLow-income subsidyTKI claimsD patientsCox regressionMedicare claimsPatientsCritical therapyBenefit phasePocket costsSpecialty drugsCost sharing